Pharmacy Times October 15, 2021
Jill Murphy, Associate Editor

They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.

A study from Gustave Roussy and the startup Owkin shows that deep learning analysis in digitized pathology slides can help classify patients with localized breast cancer between high- and low-risk of metastatic relapse in the next 5 years using artificial intelligence (AI).

This could help in therapeutic decision making and avoid unnecessary chemotherapy affecting the personal, professional, and social lives for low-risk women, according to the researchers. They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying...

Today's Sponsors

Qure4u
HLTH
ZeOmega

Today's Sponsors

Premier
TripleTree

Today's Sponsor

Transcarent

 
Topics: AI (Artificial Intelligence), Patient / Consumer, Provider, Survey / Study, Technology, Trends
What Is Conversational AI: Principles and Examples
Report: 95% of tech leaders say that AI will drive future innovation
Babylon Launches AI in Rwanda in Next Step Towards Digitising Healthcare in Rwanda
Former Google scientist Timnit Gebru has launched an AI research centre
NUHS adopts NVIDIA's AI system for real-time data streaming